Sector News

With GSK swap behind it, Novartis scouts for $2B-$5B buyouts

April 23, 2015
Life sciences
A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he’s going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.
 
“We’ve put our M&A people back to work,” Jimenez told reporters this morning, according to a report from Bloomberg. Novartis is looking past an expected approval for the heart drug LCZ696 as it scouts for new therapies that can remedy a painful loss of franchise cash to generic competition.
 
In its deal with GSK, Novartis handed over a portfolio of underperforming vaccine assets in exchange for Glaxo’s less-than-compelling cancer drug portfolio. Each of the pharma giants expects to do better by concentrating their focus on core assets.
 
For Novartis, that’s meant forming a new immuno-oncology division in Cambridge, MA, under former Dana Farber researcher Glenn Dranoff. Just weeks ago Novartis executed a $750 million tie-up with Aduro–a deal that Jimenez noted today “strengthens our presence in immuno-oncology.” And Jimenez has been an eager advocate of a growing CAR-T research operation at the University of Pennsylvania, which is reengineering T cells into cancer cell killers.
 
The CEO’s comments will do nothing to calm the frenzied expectations for more M&A in the coming months. Like just about everybody in Big Pharma, with the possible exception of Pfizer, Novartis is shunning big buyouts after a full slate of high-end mergers delivered little in the way of sustainable growth or appreciable pipeline value. The focus on new assets in the under-$10 billion category has helped swell valuations across the board in biotech. 
 
While the swap with GSK may be officially completed, there’s still a significant amount of fallout expected among rank and file staffers. While largely applauded by Wall Street, a swap like this can trigger big layoffs, as GSK has demonstrated with plans to centralize its vaccine division in Rockville, MD, while uprooting organizations in Philadelphia and Boston with hundreds of employees. Novartis has yet to reveal how it plans to integrate its new oncology assets into the company, but pink slips are likely.
 
By John Carroll
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”